(439 days)
Unknown
The summary describes automated analysis and detection, which could be implemented using traditional image processing or AI/ML. Without explicit mention of AI/ML terms or details about the algorithms used, it's impossible to definitively confirm the presence of AI/ML.
No.
The device is a computer-aided detection (CAD) system for identifying polyps, which assists in diagnosis rather than providing treatment or therapy.
Yes
The device automatically detects potential polyps in CT Colonography exams, highlights them to the interpreting physician to identify additional potential polyps that may not have been identified on initial review. This process of identifying and highlighting abnormalities is fundamental to diagnosis.
Yes
The device description explicitly states "The VeraLook is a software-based CAD system" and describes its function as receiving, analyzing, and producing information from images, without mentioning any associated hardware components provided by the manufacturer.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device function: The VeraLook™ CTC CAD analyzes medical images (CT Colonography exams) to identify potential polyps. It does not analyze biological samples from the patient.
- Intended Use: The intended use clearly states it's for detecting polyps in CT Colonography exams, which are imaging studies.
Therefore, the VeraLook™ CTC CAD falls under the category of medical imaging software or Computer-Aided Detection (CAD) software, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
iCAD's VeraLook™ CTC CAD is intended to automatically detect potential polyps in CT Colonography exams. The identified polyps can then be highlighted to the interpreting physician after initial review of the CTC exam with the intent of identifying additional potential polyps that may not have been identified on initial review.
Product codes
JAK
Device Description
The VeraLook is a software-based CAD system for detecting the location and extent of polyps in CTC exams. The product is intended to receive CTC images in standard DICOM format from any 3D workstation manufacturer, perform automated analysis on the images to identify polyps, and then produce information about the identified regions that can be received and displayed by CTC review workstations to help radiologists in the detection of polyps.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
CT Colonography exams
Anatomical Site
colon
Indicated Patient Age Range
Not Found
Intended User / Care Setting
interpreting physician, radiologists
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Non-clinical and clinical data was supplied to determine substantial equivalence to the predicate devices.
Summary of Performance Studies
Non-clinical and clinical data was supplied to determine substantial equivalence to the predicate devices.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.1750 Computed tomography x-ray system.
(a)
Identification. A computed tomography x-ray system is a diagnostic x-ray system intended to produce cross-sectional images of the body by computer reconstruction of x-ray transmission data from the same axial plane taken at different angles. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II.
0
SECTION 2: 510(K) SUMMARY AS REQUIRED BY CFR 807.92(c)
COMPANY NAME/ADDRESS/PHONE/FAX:
iCAD Inc. 98 Spitbrook Road, Suite 100 Nashua, NH 03062 T: 937-431-7945 F: 603-880-3843
AUG 0 4 2010
NAME OF CONTACT:
John A. DeLucia VP, Regulatory Affairs and Quality Assurance
DATE:
May 21, 2009
DEVICE NAME:
Computed Tomographic Colonography Computer-Aided Detection Software
TRADE NAME:
iCAD VeraLook™ CTC CAD Software
COMMON NAME:
Software for Computed Tomographic Colonography Computer-Aided Detection
CLASSIFICATION NAME:
21 CFR 892.1750 Class II System, x-ray, tomography, computed JAK
page 1 of 3
Proprietary Information of iCAD, Inc.
Page 5 of 60
1
1
NAME OF LEGALLY MARKETED DEVICE FOR WHICH A CLAIM OF SUBSTANTIAL EQIVALENCE IS MADE
iCAD's VeraLook™ CTC CAD Software is substantially equivalent to the following legally marketed predicate devices that display and visualize 2D and 3D medical image data of the colon derived from CT scans, for the purpose of assisting radiologists and other clinicians in the evaluation of polyps.
| 510(k) Reference No. | Device Name | Manufacturer |
|---|---|---|
| K042674 | Colon CAR 1.2 | Medicsight |
| K042605 | Syngo Colonography | |
| Software Package With | ||
| Extended Functionality | Siemens Ag, Medical | |
| Solutions |
DEVICE DESCRIPTION
The VeraLook is a software-based CAD system for detecting the location and extent of polyps in CTC exams. The product is intended to receive CTC images in standard DICOM format from any 3D workstation manufacturer, perform automated analysis on the images to identify polyps, and then produce information about the identified regions that can be received and displayed by CTC review workstations to help radiologists in the detection of polyps.
INDICATION FOR USE
VeraLook CTC CAD Software is intended to automatically detect potential polyps in CT Colonography exams. The identified polyps can then be highlighted to the interpreting physician after initial review of the CTC exam with the intent of identifying additional potential polyps that may not have been identified on initial review.
SUMMARY OF THE TECHNOLOGICAL CHARACTERISTICS
VeraLook CTC CAD Software has similar intended use, principles of operation, features or and characteristics as the previously cleared predicate devices. VeraLook and each of the predicate devices are intended to detect, display, visualize, and measure colon lesions or polyps. VeraLook and the predicate devices all assist the radiologist in evaluating and confirming the presence or absence of colon lesions. VeraLook also shares common workflow features and characteristics as that of the predicate devices such as DICOM 3.0 Receiving, Polyp Size and Volume Measurement, and ability to generate reports.
page 2 of 3
Page 6 of 60
2
ﺮ ﺍﻟﻤﺮﺍﺟﻊ ﺍﻟﻤﺴﺎﺣﺔ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍ
VeraLook does differ from the predicates in that VeraLook expressly claims to identify "additional potential polyps that may not have been identified on initial review". This difference in intended use from the predicate devices could raise issues of safety and effectiveness. Recognizing this, iCAD has supplied clinical data in addition to bench testing and simulations to assess safety and effectiveness of this claim.
GENERAL SAFETY AND EFFECTIVENESS CONCERNS:
The device labeling contains instructions for use and any necessary cautions and warnings to provide for safe and effective use of this device. Risk management is ensured via a risk analysis, which is used to identify potential hazards. These potential hazards are controlled via software development, verification and validation testing.
ASSESSMENT OF NON-CLINICAL AND CLINICAL PERFORMANCE DATA
Non-clinical and clinical data was supplied to determine substantial equivalence to the predicate devices.
CONCLUSION:
This 510(k) Pre-Market Notification for iCAD's VeraLook CTC CAD Software contains adequate information and data to determine substantial equivalence to the predicate devices.
page 3 of 3
3
Image /page/3/Picture/0 description: The image shows the logo for the Department of Health & Human Services - USA. The logo is circular and contains the department's name around the perimeter. Inside the circle is an abstract symbol that resembles an eagle or a bird in flight, composed of three stylized lines.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room - WO66-G609 Silver Spring, MD 20993-0002
Mr. John A. DeLucia Vice President Regulatory Affairs and Quality Assurance iCAD. Inc. 98 Spitbrook Road, Suite 100 NASHUA NH 03062
AUG 0 4 2010
Re: K091529
Trade/Device Name: VeraLook™ CTC CAD Regulation Number: 21 CFR 892.1750 Regulation Name: Computed tomography x-ray system Regulatory Class: II Product Code: JAK Dated: February 1, 2010 Received: February 2, 2010
Dear Mr. DeLucia:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of
4
medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legal) y renaketed predicate device results in a classification for your device and thus, permits your dry ince to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office
of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its tollyfre no (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Donald J. Trump
Donald J. St.Pierre Acting Director Division of Radiological Devices Office of In Vitro Diagnostic Device Evaluation and Safety . Center for Devices and Radiological Health
Enclosure
5
SECTION 1: INDICATIONS FOR USE STATEMENT
2091529 510(k) Number (if known):
Device Name: VeraLook™ CTC CAD
AUG Q 4 2010
Indications for Use:
iCAD's VeraLook™ CTC CAD is intended to automatically detect potential polyps in CT Colonography exams. The identified polyps can then be highlighted to the interpreting physician after initial review of the CTC exam with the intent of identifying additional potential polyps that may not have been identified on initial review.
Prescription Use (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Breater Bratication (@DB) (
Page 1 of 1
(Posted November 13, 2003)
(Division Sign-Off)
Division of Radiological Devices Office of In Vitro Diagnostic Devices
Office of In Vitro Diagnostic Devices
Office of In Vitro Diagnostic Device Evaluation and Safety
510K. K091529
Proprietary Information of iCAD, Inc.